About Aspire Biopharma
Aspire Biopharma is a publicly listed company based in United States founded in 2021. Biopharmaceutical drug formulations are developed for various medical conditions. Aspire Biopharma has completed 1 acquisition, including Dura-Shiloh. Its chief executive, as recorded, is Kraig Higginson. Aspire Biopharma offers products and services including Sublingual Aspirin and Soluble Formulations. Its focus areas include Life Sciences, Pain Management, Drugs and Diversified. Its legal entity is Aspire BioPharma Inc. Its competitors include Flexion Therapeutics, Cara Therapeutics and Eliem Therapeutics; 3 of its 3 listed competitors have raised funding.
Company details
Aspire Biopharma was founded in 2021 and is based in Puerto Rico. Operations focus on the biopharmaceutical sector, where drug formulations are developed to address multiple medical conditions. Instaprin is offered as a granular or powder formulation of a soluble compound, targeted at cardiology emergencies and pain management. The company maintains a presence through its domain, aspirebiolabs.com, with Kraig Higginson serving as CEO.
- Headquarters Puerto Rico
- Stage Public
- SectorsHealthcare
- Email••••••••
- Phone•••• ••••
- Website aspirebiolabs.com
- Social LinkedIn
- Legal Name Aspire Biopharma Inc.
- Annual Revenue$6.2 K (USD)as on Dec 31, 2025
- Net Profit-$24.48 M (USD)-1768.95as on Dec 31, 2025
- EBITDA-$19.35 M (USD)-1498.13as on Dec 31, 2025
- Investments & Acquisitions
Products & Services of Aspire Biopharma
Aspire Biopharma offers a comprehensive portfolio of products and services, including Sublingual Aspirin and Soluble Formulations.
Fast-acting aspirin for pain relief via sublingual absorption.
Innovative formulations for instant drug absorption and efficacy.
Funding Insights of Aspire Biopharma
- Total Rounds 2
- First Round $1M
(Sep 2025)
All 2 funding rounds of Aspire Biopharma with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Feb 2026 | $21M | Post-IPO | – | – | – |
| Sep 2025 | $1M | Post-IPO | – | – | – |
People of Aspire Biopharma
1 people are tracked at Aspire Biopharma (1 in leadership).
| Name | Role | Group |
|---|---|---|
Kraig Higginson | CEO | Leadership |
Complete people profiles for Aspire Biopharma
Full employee and board profiles, team structure, tenure and professional contact details require an active premium plan.
- Full employee list
- Team structure
- Board tenure
- Professional contacts
Verified entity values are shown only after access is granted.
IPO & Listings of Aspire Biopharma
Aspire Biopharma is a publicly listed company on the NASDAQ with ticker symbol ASBP in USA, operating in the Health technology sector. As a publicly traded entity, the company provides investors with opportunities to participate in its growth story through equity ownership. The listing enables access to capital markets, enhances corporate visibility, and provides liquidity for shareholders while maintaining transparency through regulatory compliance and regular financial disclosures.
- IPO date11 Apr 2022
- Listed onNASDAQ: ASBP
- Listed entityAspire Biopharma Holdings, Inc.
- Exchange sectorHealth technology
Investments & Acquisitions by Aspire Biopharma
Aspire Biopharma has strategically engaged in corporate development activities, having acquired 1 company. Notable acquisitions include Dura-Shiloh.
| Company Name | Description | Domain | Location | Founded | Acquired | Amount |
|---|---|---|---|---|---|---|
Manufactures automotive parts for electrification, safety, and performance globally. | durashiloh.com | Auburn Hills, United States | 1914 | Jun 2026 | •••• |
Complete acquisition details for Aspire Biopharma
Acquired stakes, deal sources and the complete acquisition history require an active premium plan.
- Acquired stakes
- Deal sources
- Complete history
- Exports
Verified entity values are shown only after access is granted.
Timeline of Aspire Biopharma
5 dated milestones of Aspire Biopharma across 5 years, from founding to its latest funding, stage changes and deals.
- Founded Aspire Biopharma is founded.
- IPO Lists on the stock exchange (IPO).
- Funding First funding round of $1.0M.
- Funding Latest funding round, Post-IPO,.
- Acquisition Acquires Dura-Shiloh.
Competitors of Aspire Biopharma
Aspire Biopharma has 3 listed competitors in our database, 3 of them funded. They include Flexion Therapeutics, Cara Therapeutics and Eliem Therapeutics.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| flexiontherapeutics.com | 2007 | Woburn, United States | $62M | 692 | Developer of therapies for the treatment of musculoskeletal disorders | |
| caratherapeutics.com | 2004 | New York, United States | $51M | 79 | Developer of therapeutics for pain relief and inflammatory diseases | |
| eliemtx.com | 2018 | Boston, United States | $171.3M | 30 | Develops antibody-based treatments for autoimmune and inflammatory disorders. |
Detailed competitors of Aspire Biopharma
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Aspire Biopharma
The website of Aspire Biopharma (aspirebiolabs.com) receives about 4.2K visits a month.
- Monthly visits4.2K
▼ 19.3% vs previous month
Top companies in Pain Management
3 companies that operate in the same segment as Aspire Biopharma (Pain Management) in United States, ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Developer of therapies for the treatment of musculoskeletal disorders | 2007 | Woburn, Massachusetts, United States | USD 62 M | USD 85.55 M | 692 | |
Developer of therapeutics for pain relief and inflammatory diseases | 2004 | New York, New York, United States | USD 51 M | USD 4.33 M | 79 | |
GPCR ligand-based therapeutics for cardiovascular diseases and pain are developed. | 2007 | Philadelphia, Pennsylvania, United States | USD 203 M | USD 3.13 M | 35 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Related news about Aspire Biopharma
Complete news archive for Aspire Biopharma
Full article history, source details, and older brand coverage require an active premium plan.
- Full article archive
- Source and publication date
- Older coverage
- Brand-specific news history
Verified entity values are shown only after access is granted.
Frequently Asked Questions about Aspire Biopharma
Aspire Biopharma was founded in 2021 and raised its 1st funding round 4 years after it was founded.
Aspire Biopharma is headquartered in United States. It is registered at Puerto Rico, United States.
Kraig Higginson is the CEO of Aspire Biopharma, as recorded in our data.
Annual revenue of Aspire Biopharma is $6.2K as on Dec 31, 2025.
Aspire Biopharma was founded in 2021 and is based in Puerto Rico. Operations focus on the biopharmaceutical sector, where drug formulations are developed to address multiple medical conditions. Instaprin is offered as a granular or powder formulation of a soluble compound, targeted at cardiology emergencies and pain management. The company maintains a presence through its domain, aspirebiolabs.com, with Kraig Higginson serving as CEO.
Aspire Biopharma's top competitors include Flexion Therapeutics, Cara Therapeutics and Eliem Therapeutics.
Aspire Biopharma offers Sublingual Aspirin and Soluble Formulations.
Yes, Aspire Biopharma is publicly traded on NASDAQ under the ticker symbol ASBP.
Aspire Biopharma has made 1 acquisition, including Dura-Shiloh.
Aspire Biopharma operates through Aspire Biopharma Inc..